FACTORS ASSOCIATED RICKETTSIOSIS MORTALITY IN NORTHWEST MEXICO

Lastra Jiménez, Zaira

FACTORS ASSOCIATED RICKETTSIOSIS MORTALITY IN NORTHWEST MEXICO

Sunday, 17 August 2014

Exhibit hall (Dena'ina Center)

Porfirio Felipe Hernández Bautista, MD , Hospital General Regional No 1,Instituto Mexicano del Seguro Social, Ciudad Obregón, Mexico

Fredy Gerardo Lucatero Castillo, MD , Unidad de Medicina Familiar 39 - Instituto Mexicano del Seguro Social, Tecate, Mexico

Jesus Mendoza Cazares, MD , Jurisdiccion Sanitaria IV - Servicios de Salud Pública del Estado de Sonora, Ciudad Obregón, Mexico

Citlalli Sandoval Duarte, MD , Hospital General Regional No 1 - Instituto Mexicano del Seguro Social, Ciudad Obregón, Mexico

Zaira Lastra Jiménez, MD , Hospital General Regional No 1- Instituto Mexicano del Seguro Social, Ciudad Obregón, Mexico

INTRODUCTION: Rickettsial diseases remains a public health problem in Northwest Mexico, for which we propose To determine mortality and factors associate Rickettsiosis.

METHODS:

A retrospective cohort study, it took all information rickettsiosis cases, which are in the nominal list of the health jurisdiction IV of Sonora, Mexico. The data collection period was from January 2008 to December 2012. The information was collected from medical records, to integrate the database. We performed a descriptive and inferential statistical analysis to detect the frequency and factors associated with rickettsial diseases.

RESULTS:

A total of 282 patients with a diagnosis of rickettsiosis, finding a total of 31 deaths, with a mortality of 11%. Only data from the period 2008 to 2011 were analyzed. The risk factors presented were ≤ 5 years of age (RR, 7.22, 95% CI, 3.78-13.81), the time interval between the start of treatment and the onset of symptoms> 5 days (RR, 2.42; 95% CI, 0.96-6.35), use of trimethoprim-sulfamethoxazole (RR, 2.65, 95% CI, 0.93-7.52), chloramphenicol (RR, 9.07, 95% CI, 4.68-17.56), gamma globulin (RR, 9.7; 95% CI, 5.19-17.79), corticosteroids (RR, 12; 95% CI, 6.05-23.77) and use of doxycycline (RR, 0.14, 95% CI, .07 to .29).

CONCLUSIONS:

We present a high mortality and major associated factors are age less than 5 years, an interval of time between the start of treatment and the onset of symptoms more than five days, the use of trimethoprim-sulfamethoxazole, chloramphenicol and corticosteroids. Doxycycline therapy reduced mortality.